Newsroom

U.S. FDA Approves the Labeling Update of Abilify Maintena® (Aripiprazole) for Extended-Release Injectable Suspension to Describe New Clinical Data for the Treatment of Acutely Relapsed Adults with Schizophrenia

December 6, 2014 - 12:00am

Yahoo!Finance
December 6, 2014
U.S. FDA Approves the Labeling Update of Abilify Maintena® (Aripiprazole) for Extended-Release Injectable Suspension to Describe New Clinical Data for the Treatment of Acutely Relapsed Adults with Schizophrenia

Focus onHealth TV

Our representatives are available to schedule your appointment on weekdays from 8am to 8pm and weekends from 9am to 5pm. You may also leave a voicemail message after regular business hours, and we will return your call.